Pulmonary Arterial Hypertension Market size was valued at US$ 5.97 Bn in 2021 and the total revenue is expected to grow at 4.9 % through 2022 to 2029, reaching nearly US$ 8.76 Bn.
Pulmonary Arterial Hypertension Market Overview
The recent research report by Maximize Market Research presents a Pulmonary Arterial Hypertension Market. The report mainly focuses on the key players and their market segments, business stratagem, regional expansion, production and pricing with cost structure. The report insights about top players, market size, share, key drivers, challenges, opportunities, competitive landscape, market attractiveness analysis, new product launches, technological innovations, and growth contributors which helps to analyse the Pulmonary Arterial Hypertension market.
For detail insights on this market, request for methodology here
@ https://www.maximizemarketresearch.com/request-sample/122335
Pulmonary Arterial Hypertension Market Dynamics
The market is expected to grow significantly over the projected period as a result of the rising prevalence of PAH (pulmonary arterial hypertension), the growing older population, and increased government support for the development of orphan medications. However, the prevalence of the PAH component has risen recently as a result of a number of factors, such as an unhealthy lifestyle, inactivity, an increase in HIV patients, excessive alcohol and tobacco use, and other idiopathic disorders. People who have pulmonary arterial hypertension are more likely to get COVID-19. According to the American College of Cardiology, there were 2.1 incidences of COVID-19 infection for per 1,000 PAH patients as of August 2021. As a result, the need for PAH medicines to treat COVID-19 increased.
Pulmonary Arterial Hypertension Market Report Scope and Research Methodology
The report on the Pulmonary Arterial Hypertension market offers details of the applications and key strategies in the market with different driving and restraining factors. The report contains the study of market trends, volume, cost, share, supply and demand, and product analysis. The qualitative and quantitative data collected by primary research resources, free and paid databases, surveys, Google forms, etc. is further analysed by tools such as SWOT and PESTLE analysis to understand the Pulmonary Arterial Hypertension market.
Pulmonary Arterial Hypertension Market Regional Insights
Regional analysis of a Pulmonary Arterial Hypertension market research report contributes insights into how the Pulmonary Arterial Hypertension market varies across different geographic regions. A regional analysis typically includes a precise examination of market trends, competitive landscape, consumer behaviour, and regulatory environment in each region.
Pulmonary Arterial Hypertension Market Segmentation
With a predicted market share of 45% in 2021, prostacyclin and its analogs are predicted to dominate the expansion of the pulmonary arterial hypertension market. The expansion is linked to both the rise in serious illnesses and the rising demand for medications. Due to the rising demand for oral prostacyclin sub-segments such Uptravi and Orenitram, the prostacyclin and analogs market is expected to experience noticeable growth over the forecast period. Additionally, prostaglandin I-2 (PGI-2), sometimes referred to as prosstacyclin, is a small lipid eicosanoid molecule produced by endothelial cells that acts locally to inhibit platelet activity and induce vasodilation. Analogs of prostacyclin have been investigated as possible therapies for arterial hypertension of the lungs (PAH).
The SGC (Soluble Guanylate Cyclase) simulators market is expected to expand at the fastest pace of 12.3% between 2022 and 2029. SGC (Soluble Guanylate Cyclase) stimulators can ensure maximum SGC activation by amplifying NO-SGC signaling. Riociguat (Adempas from the Bayer corporation), the only medicine approved for PAH (Pulmonary Arterial Hypertension), falls within this group. Additionally, it is anticipated that ERA and PDE-5 sectors will have considerable growth and drive market expansion in the years to come.
Market Size (Value) Estimates & Forecast By Drug Class, 2021-2029
1. Prostacyclin and Prostacyclin Analogs
2. Soluble Guanylate Cyclase (SGC) Stimulators
3. Endothelin Receptor Antagonist (ERA)
4. Phosphodiesterase 5 (PDE-5)
For any Queries Linked with the Report, Ask an Analyst
@ https://www.maximizemarketresearch.com/request-sample/122335
Pulmonary Arterial Hypertension Market Key Players
- Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.
• United Therapeutics Corporation
• GlaxoSmithKline Plc. (GSK);
• Roivant Sciences
• Accredo.
• Liquidia Corporation
• Pfizer, Inc.
• Acceleron Pharma, Inc.
• Bayer AG
• Janssen Türkiye
• Trident Life Sciences Ltd
• PhaseBio Pharmaceuticals, Inc.
• Domedica
• Biozeus Biopharmaceuticals
Key questions answered in Pulmonary Arterial Hypertension Market are:
- What is the Pulmonary Arterial Hypertension market size of the dominating region?
- What was the Pulmonary Arterial Hypertension market size in 2022?
- What is the expected Pulmonary Arterial Hypertension market size by 2029?
- What is the growth rate of the Pulmonary Arterial Hypertension Market?
- Which are the factors expected to drive the Pulmonary Arterial Hypertension market growth?
Key Offerings:
- Past Market Size and Competitive Landscape (2018 to 2021)
- Past Pricing and price curve by region (2018 to 2021)
- Market Size, Share, Size & Forecast by different segment | 2022−2029
- Market Dynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by region
- Market Segmentation – A detailed analysis by segment with their sub-segments and Region
- Competitive Landscape – Profiles of selected key players by region from a strategic perspective
- Competitive landscape – Market Leaders, Market Followers, Regional player
- Competitive benchmarking of key players by region
- PESTLE Analysis
- PORTER’s analysis
- Value chain and supply chain analysis
- Legal Aspects of business by region
- Lucrative business opportunities with SWOT analysis
- Recommendations
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
+91 96071 95908, +91 9607365656
Related Reports:
Aviation Fuel Market https://www.maximizemarketresearch.com/market-report/global-aviation-fuel-market/97611/
